EuroPCR 2023: FAST-TAVI II highlights benefits of reducing length of stay after TAVI procedures


Implementation of a dedicated training programme allowed hospitals to increase the number of patients discharged early from hospital within 72 hours of undergoing a transfemoral transcatheter aortic valve implantation (TAVI) procedure. This was the finding of the multicentre, randomised FAST-TAVI II trial, findings of which were presented at EuroPCR 2023 (16–19 May, Paris, France) by Eric Durand (Rouen University Hospital Center, Rouen, France).

Speaking to Cardiovascular News, Durand unpacks the findings of the trial, details why early discharge after TAVI could be beneficial to both healthcare providers and patients, and discusses how centres can implement their own early discharge programme.


Please enter your comment!
Please enter your name here